Latest Net Tangible Assets News

Boss Energy reported a sharp turnaround with a $34.2 million net loss for FY2025 despite generating $75.6 million in revenue, while withholding dividends amid ongoing challenges.

Pathkey.AI Ltd reported a substantial reduction in its annual loss to $1.45 million for FY2025, despite a dramatic 93% plunge in revenue to just $27,783. The company’s financials reveal a cautious recovery phase with significant equity injections and a new cryptocurrency investment.

Vection Technologies reported a 9.6% revenue increase to $36 million and a 25.3% reduction in net loss for FY2025, driven by operational improvements and a key acquisition.

The Calmer Co. International Limited reported a strong revenue increase of 88% for the year ended June 2025, yet the company still recorded a net loss of nearly $4 million, with no dividends declared.

Visionflex Group Limited reported a sharp 33% decline in revenues and a 69% increase in net losses for FY25, with auditors flagging material uncertainty over the company’s ability to continue as a going concern.

Island Pharmaceuticals reported a $3.92 million loss for FY2025 despite an 86% increase in income, with no dividends declared.

Bhagwan Marine Limited reported a robust 5.3% revenue increase and a striking 125% surge in net profit for FY25, announcing its inaugural fully franked dividend.

TrivarX Limited reported a reduced net loss of $943K for FY25 alongside a $3.68 million equity raise, yet flagged material uncertainty over its ability to continue as a going concern.

Hiremii Limited reported a near-flat revenue for FY2025 with a 25% increase in net loss, while pushing forward its AI-driven recruitment platform and completing a key acquisition to expand market reach.

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

Orion Equities reported a $1.33 million net profit for FY25, down 56% from the prior year, impacted by unrealised losses on key investments and a significant tax benefit reversal. The company’s portfolio remains anchored by stakes in Bentley Capital and Strike Resources.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.